Risk Evaluation and Mitigation (REMS and EU-RMP)

PRA understands that clinical research and safety surveillance after authorization have become increasingly important due to: 

  • A highly competitive global market 
  • Increasing regulatory demands for additional data at post-approval phase 

We offer clients a range of expertise in planning studies, including: 

  • Setting up operational capability 
  • Risk management 
  • Use of our innovative “Tiered Approach” for designing and implementing Risk Evaluation and Mitigation Strategies (REMS) and EU-Risk Management Plan (EU-RMP) activities 

The PRA “Tiered Approach” allows: 

  • Each REMS/EU-RMP component to be placed in one of three relevant tiers according to complexity 
  • Proven systems and processes to be adapted to meet each sponsor’s needs 
  • The flexibility to expand a program as the lifecycle of a product or study evolves